MetLife Investment Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

MetLife Investment Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-14,651	Closed	-$703K	–	2411
2020 Q1	$703K	Hold	14,651	–	–	0.01%	1052
2019 Q4	$688K	Hold	14,651	–	–	0.01%	1284
2019 Q3	$346K	Hold	14,651	–	–	﹤0.01%	1621
2019 Q2	$441K	Buy	14,651 +7,136	+95%	+$163K	﹤0.01%	1556
2019 Q1	$168K	Hold	7,515	–	–	﹤0.01%	2063
2018 Q4	$137K	Buy	+7,515	New	+$118K	﹤0.01%	2128

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

MetLife Investment Management's RARX Position: Q2 2020 in Review

MetLife Investment Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 14,651 shares — an estimated $703K sold.

MetLife Investment Management first reported a position in RARX in Q4 2018 and held it in 6 quarters. The position peaked at $703K in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

MetLife Investment Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
MetLife Investment Management sold 14,651 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $703K.
MetLife Investment Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 6 quarters.
MetLife Investment Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $703K in Q1 2020.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on MetLife Investment Management's 13F filing for Q2 2020, filed 14 Aug 2020.